Nelarabin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nelarabin" in Serbian language version.

refsWebsite

Global rank Serbian rank

10doi.org

2^nd place

4^th place

9nih.gov

4^th place

8^th place

1harvard.edu

18^th place

28^th place

doi.org

Buie, L. W.; Epstein, S. S.; Lindley, C. M. (септембар 2007). „Nelarabine: A novel purine antimetabolite antineoplastic agent”. Clin Ther. 29 (9): 1887—99. PMID 18035189. doi:10.1016/j.clinthera.2007.09.002.
Deangelo, D. J. (октобар 2009). „Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma”. Hematol Oncol Clin North Am. 23 (5): 1121—35. PMID 19825456. doi:10.1016/j.hoc.2009.07.008.
Roecker, A. M.; Allison, J. C.; Kisor, D. F. (август 2006). „Nelarabine: Efficacy in the treatment of clinical malignancies”. Future Oncol. 2 (4): 441—8. PMID 16922610. doi:10.2217/14796694.2.4.441.
Sanford, M.; Lyseng-Williamson, K. A. (2008). „Nelarabine”. Drugs. 68 (4): 439—47. PMID 18318562. doi:10.2165/00003495-200868040-00004.
Reilly, K. M.; Kisor, D. F. (фебруар 2009). „Profile of nelarabine: Use in the treatment of T-cell acute lymphoblastic leukemia”. Onco Targets Ther. 18 (2): 219—28. PMC 2886323 . PMID 20616909. doi:10.2147/ott.s4770 .
Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

harvard.edu

adsabs.harvard.edu

Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

nih.gov

ncbi.nlm.nih.gov

Buie, L. W.; Epstein, S. S.; Lindley, C. M. (септембар 2007). „Nelarabine: A novel purine antimetabolite antineoplastic agent”. Clin Ther. 29 (9): 1887—99. PMID 18035189. doi:10.1016/j.clinthera.2007.09.002.
Deangelo, D. J. (октобар 2009). „Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma”. Hematol Oncol Clin North Am. 23 (5): 1121—35. PMID 19825456. doi:10.1016/j.hoc.2009.07.008.
Roecker, A. M.; Allison, J. C.; Kisor, D. F. (август 2006). „Nelarabine: Efficacy in the treatment of clinical malignancies”. Future Oncol. 2 (4): 441—8. PMID 16922610. doi:10.2217/14796694.2.4.441.
Sanford, M.; Lyseng-Williamson, K. A. (2008). „Nelarabine”. Drugs. 68 (4): 439—47. PMID 18318562. doi:10.2165/00003495-200868040-00004.
Reilly, K. M.; Kisor, D. F. (фебруар 2009). „Profile of nelarabine: Use in the treatment of T-cell acute lymphoblastic leukemia”. Onco Targets Ther. 18 (2): 219—28. PMC 2886323 . PMID 20616909. doi:10.2147/ott.s4770 .
Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.